Xenetic Biosciences (formally Lipoxen) is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs.
The company has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Xenetic Biosciences 's technologies include: PolyXen® - Protein drug delivery, ImuXen® - DNA, protein and polysaccharide vaccines and VesicALL® - Anti-cancer drugs using liposomal entrapment.
14/05/12
Xenetic Biosciences makes 'pivotal' development appointment - update14/05/12
Xenetic Biosciences makes 'pivotal' development appointment03/05/12
Xenetic Biosciences appoints special consultant to drive development of OncoHist candidate30/04/12
Xenetic Biosciences calls Dr Artur Isaev to the board as Igor Nikolaev resigns02/03/12
Xenetic Bioscience's share plan means good news for management is positive for shareholders - Singer13/02/12
Xenetic Biosciences doses its first intravenous patient with ErepoXen01/02/12
Xenetic Biosciences suspends open offer part of fundraising23/01/12
Xenetic dismisses SIL stake sale report04/01/12
Xenetic threatens to scrap SymbioTec acquisition15/12/11
Xenetic Biosciences reports slight delay in completing German acquisition29/11/11
Xenetic Biosciences raises £12.2 million via share subscription26/10/11
Xenetic Biosciences begins process to close SynBio and SymbioTec deals30/09/11
Xenetic Biosciences to close German and Russian transactions by end of October09/09/11
Xenetic Biosciences to take part in UK-Russia trade trip08/09/11
Xenetic to go ahead with ‘co-delivery technology’ patent in US24/08/11
Lipoxen reduced H1 losses ahead of transformative acquisition03/06/11
Lipoxen says its technology platforms will prove their potential04/05/11
Lipoxen awarded US$100,000 grant to develop polio vaccine15/04/11
GE&CR initiates Lipoxen coverage with 'cautious' 30.7p price target05/04/11
Lipoxen shares rise as International Aids Vaccine Initiative collaboration extended16/12/10
Lipoxen reports encouraging phase II results for ErepoXen29/11/10
Lipoxen’s Russian drug development partner lands £10.7 mln IPO on MICEX18/10/10
Lipoxen to accelerate ImuXen flu vaccine to phase 1 trial within 24 months after positive data16/09/10
Singer Capital hails Lipoxen’s revised Baxter agreement , looks to PolyXen results13/08/10
Lipoxen founder Gregoriadis receives prestigious Founders Award21/06/10
Lipoxen extends PolyXen patent family in the US14/06/10
Lipoxen and Baxter confident that PolyXen-based haemophilia treatments will move into clinical devel26/05/10
Lipoxen expands its US DNA Vaccine Patent for ImuXen28/04/10
Lipoxen receives positive results for ImuXen candidates for influenza and malaria26/04/10
Lipoxen CEO, CFO buy 250,000 further shares in company01/04/10
Lipoxen expects significant license fee income from project base, raises £1.2m05/02/10
Lipoxen H2 revenue hit by EPO and Insulin delays, foresees positive news flow in 201014/01/10
Lipoxen's PolyXen bio-polymer technology wins US Patent16/11/09
Lipoxen in research collaboration with Russia’s Pharmsynthez30/09/09
Lipoxen narrows H1 losses, named lead company in UK vaccine research programme24/08/09
Lipoxen CEO Scott Maguire talks about the company's potential blockbuster applications29/06/09
Lipoxen wins DNA vaccine patent in EU and US for ImuXen23/06/09
Lipoxen in evaluation agreement for gene silencing technology siRNAblate29/05/09
Lipoxen successfully raises £2.9 million, Baxter International and five directors participate13/05/09
Lipoxen secures Malaria initiative funding and US govt agency expertise for drug technology trial12/02/08
Lipoxen receives US patent
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
